Thus, the combination therapy of this novel vaccine with PD-1 blockade may have great potential as a new treatment strategy for the treatment of other cancers, such as mesothelioma, pancreatic cancer, ovarian cancer and triple negative breast cancer with high expression of MSLN. The gene discussed is MSLN; the disease is triple-negative breast carcinoma.